AT396425B - Verfahren zur herstellung von zusammensetzungen, die stoffe anhaltend abgeben und so erhaltene zusammensetzungen - Google Patents

Verfahren zur herstellung von zusammensetzungen, die stoffe anhaltend abgeben und so erhaltene zusammensetzungen Download PDF

Info

Publication number
AT396425B
AT396425B AT0152591A AT152591A AT396425B AT 396425 B AT396425 B AT 396425B AT 0152591 A AT0152591 A AT 0152591A AT 152591 A AT152591 A AT 152591A AT 396425 B AT396425 B AT 396425B
Authority
AT
Austria
Prior art keywords
gel
particles
phase
mpa
active ingredient
Prior art date
Application number
AT0152591A
Other languages
German (de)
English (en)
Other versions
ATA152591A (de
Inventor
Jean-Marc Ruiz
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of ATA152591A publication Critical patent/ATA152591A/de
Application granted granted Critical
Publication of AT396425B publication Critical patent/AT396425B/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Glanulating (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT0152591A 1990-08-01 1991-07-31 Verfahren zur herstellung von zusammensetzungen, die stoffe anhaltend abgeben und so erhaltene zusammensetzungen AT396425B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909016885A GB9016885D0 (en) 1990-08-01 1990-08-01 Sustained release pharmaceutical compositions

Publications (2)

Publication Number Publication Date
ATA152591A ATA152591A (de) 1993-01-15
AT396425B true AT396425B (de) 1993-09-27

Family

ID=10679993

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0152591A AT396425B (de) 1990-08-01 1991-07-31 Verfahren zur herstellung von zusammensetzungen, die stoffe anhaltend abgeben und so erhaltene zusammensetzungen

Country Status (30)

Country Link
US (1) US5213812A (cg-RX-API-DMAC7.html)
JP (1) JP2818704B2 (cg-RX-API-DMAC7.html)
KR (1) KR920003962A (cg-RX-API-DMAC7.html)
AT (1) AT396425B (cg-RX-API-DMAC7.html)
AU (2) AU649696B2 (cg-RX-API-DMAC7.html)
BE (1) BE1004772A3 (cg-RX-API-DMAC7.html)
CA (1) CA2048270C (cg-RX-API-DMAC7.html)
CH (1) CH682715A5 (cg-RX-API-DMAC7.html)
DE (1) DE4125542A1 (cg-RX-API-DMAC7.html)
DK (1) DK175756B1 (cg-RX-API-DMAC7.html)
ES (1) ES2046083B1 (cg-RX-API-DMAC7.html)
FI (1) FI104149B1 (cg-RX-API-DMAC7.html)
FR (1) FR2665360B1 (cg-RX-API-DMAC7.html)
GB (1) GB9016885D0 (cg-RX-API-DMAC7.html)
GR (1) GR1001512B (cg-RX-API-DMAC7.html)
HK (1) HK33294A (cg-RX-API-DMAC7.html)
IE (1) IE65124B1 (cg-RX-API-DMAC7.html)
IN (1) IN178446B (cg-RX-API-DMAC7.html)
IT (1) IT1251788B (cg-RX-API-DMAC7.html)
LU (1) LU87982A1 (cg-RX-API-DMAC7.html)
MA (1) MA22245A1 (cg-RX-API-DMAC7.html)
MY (1) MY107500A (cg-RX-API-DMAC7.html)
NL (1) NL194637C (cg-RX-API-DMAC7.html)
NO (1) NO300158B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ238981A (cg-RX-API-DMAC7.html)
OA (1) OA09387A (cg-RX-API-DMAC7.html)
PT (1) PT98497B (cg-RX-API-DMAC7.html)
SE (1) SE505734C2 (cg-RX-API-DMAC7.html)
TN (1) TNSN91067A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA915565B (cg-RX-API-DMAC7.html)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
GB9310030D0 (en) * 1993-05-15 1993-06-30 Scras Dry processed particles and process for the preparation of the same
US5569467A (en) * 1993-05-15 1996-10-29 Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.) Process for the preparation of microballs and microballs thus obtained
WO1995022963A1 (en) * 1994-02-28 1995-08-31 Medinova Medical Consulting Gmbh Drug targeting system, method for preparing same and its use
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
DE19604744A1 (de) 1996-02-09 1997-08-14 Henkel Kgaa Technische Di-/Triglyceridgemische
DE19617137C1 (de) * 1996-04-29 1997-02-27 Henkel Kgaa Verwendung von Copolymerestern für die Herstellung von Mikrosphären
EP0930874A2 (en) * 1996-10-09 1999-07-28 Takeda Chemical Industries, Ltd. A method for producing a microparticle
AR012448A1 (es) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
WO1999052708A1 (en) 1998-04-13 1999-10-21 Luminex Corporation Liquid labeling with fluorescent microparticles
KR100707710B1 (ko) * 1998-12-16 2007-04-18 아벤티스 파마슈티칼스 인크. 생분해가능한 중합체로 캡슐화된 세로토닌 수용체 길항제및 이의 제조방법
AU5644400A (en) * 1999-09-24 2001-03-29 Rohm And Haas Company Pellet compositions
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
DE60138641D1 (de) 2000-10-27 2009-06-18 Baxter Healthcare Sa Herstellung von mikrokügelchen
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
ATE395042T1 (de) * 2001-08-16 2008-05-15 Baxter Int Darreichungsformen welche mikropartikel und treibgas enthalten
FR2848113B1 (fr) * 2002-12-04 2005-02-25 Oreal Stabilisation de principes actifs aromatiques par des polymeres aromatiques
US20040166077A1 (en) * 2002-12-04 2004-08-26 L'oreal Process for treating keratin materials with aromatic active principles
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
KR101137785B1 (ko) * 2003-07-18 2012-04-25 백스터 인터내셔널 인코포레이티드 제어된 상 분리에 의해 제조된 작은 구형 입자의 제조방법, 이용 방법 및 조성물
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
AU2004258971A1 (en) * 2003-07-22 2005-02-03 Baxter Healthcare S.A. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
US20060135277A1 (en) * 2003-09-10 2006-06-22 Marnocha Bendict F Golf club and practice arrangement
FR2865938B1 (fr) * 2004-02-05 2006-06-02 Sod Conseils Rech Applic Formulation retard solide comprenant de l'acetate de triptoreline
MXPA06012992A (es) * 2004-05-12 2007-02-12 Baxter Int Microesferas que comprenden proteina y que muestran inyectabilidad en altas concentraciones de este agente.
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
US7884085B2 (en) * 2004-05-12 2011-02-08 Baxter International Inc. Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
DK2072040T3 (da) 2004-05-12 2013-07-29 Baxter Healthcare Sa Terapeutisk anvendelse af nukleinsyremikrokugler
US20060127486A1 (en) * 2004-07-13 2006-06-15 Moerck Rudi E Ceramic structures for prevention of drug diversion
WO2006017337A1 (en) * 2004-07-13 2006-02-16 Altairnano, Inc. Ceramic structures for controlled release of drugs
WO2006050345A1 (en) * 2004-10-29 2006-05-11 Adhesives Research, Inc. Microscopic tagging system for security identification
CN101188996B (zh) * 2005-04-27 2013-03-27 巴克斯特国际公司 表面改性的微粒及其形成和使用方法
AU2006283170A1 (en) * 2005-08-23 2007-03-01 Altairnano, Inc. Highly photocatalytic phosphorus-doped anatase-TiO2 composition and related manufacturing methods
US20080020175A1 (en) * 2006-03-02 2008-01-24 Fred Ratel Nanostructured Indium-Doped Iron Oxide
US20080044638A1 (en) * 2006-03-02 2008-02-21 Fred Ratel Nanostructured Metal Oxides
WO2007103812A1 (en) * 2006-03-02 2007-09-13 Altairnano, Inc. Method for low temperature production of nano-structured iron oxide coatings
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
CA2942128C (en) 2006-08-04 2019-11-26 Baxter Healthcare S.A. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
US20080248122A1 (en) * 2006-10-06 2008-10-09 Baxter International Inc. Microencapsules Containing Surface-Modified Microparticles And Methods Of Forming And Using The Same
WO2008043157A1 (en) 2006-10-12 2008-04-17 The University Of Queensland Compositions and methods for modulating immune responses
US20090169628A1 (en) 2006-10-17 2009-07-02 Armark Authentication Technologies, Llc Article and method for focused delivery of therapeutic and/or diagnostic materials
WO2008128000A1 (en) * 2007-04-12 2008-10-23 Altairnano, Inc. Teflon replacements and related production methods
US8808747B2 (en) * 2007-04-17 2014-08-19 Baxter International Inc. Nucleic acid microparticles for pulmonary delivery
US9782300B2 (en) 2008-02-01 2017-10-10 Kci Licensing, Inc. Fiber-microsphere bioresorbable composite scaffold for wound healing
WO2009129544A1 (en) 2008-04-18 2009-10-22 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
US8323615B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8367427B2 (en) * 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US20100078848A1 (en) * 2008-09-29 2010-04-01 Armark Authentication Technologies, Llc Spinneret and method of spinning fiber
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
WO2010132763A1 (en) * 2009-05-15 2010-11-18 Armark Authentication Technologies, Llc Fiber having non-uniform composition and method for making same
EP2435094A2 (en) 2009-05-27 2012-04-04 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
WO2011038053A1 (en) * 2009-09-25 2011-03-31 Armark Authentication Technologies, Llc Tissue fiber scaffold and method for making
CA2798323A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
EP2399931A1 (fr) * 2010-06-22 2011-12-28 Ipsen Pharma S.A.S. Nouveaux composés octapeptidiques et leur utilisation thérapeutique
AU2011325857A1 (en) 2010-11-01 2013-05-02 University Of Technology, Sydney Immune-modulating agents and uses therefor
MX2014001142A (es) 2011-07-29 2014-02-27 Selecta Biosciences Inc Nanoportadores sinteticos que generan respuestas inmunitarias humorales y de linfocitos t citotoxicos (ctl).
ES2936067T3 (es) 2014-05-27 2023-03-14 Univ Queensland IL-22 para uso en el tratamiento de trastornos metabólicos
FR3067226B1 (fr) * 2017-06-13 2021-10-08 Rossignol Lange Element de chaussure de ski

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0145240A2 (en) * 1983-11-04 1985-06-19 Takeda Chemical Industries, Ltd. Method for producing Microcapsule

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3567650A (en) * 1969-02-14 1971-03-02 Ncr Co Method of making microscopic capsules
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
IN167096B (cg-RX-API-DMAC7.html) * 1985-04-04 1990-09-01 Akzo Nv
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8628728D0 (en) * 1986-12-02 1987-01-07 Euro Celtique Sa Spheroids
GB8705083D0 (en) * 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
EP0366058A3 (en) * 1988-10-27 1991-03-20 Abbott Laboratories Controlled-release delivery device, method for producing device, and method of using device

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0145240A2 (en) * 1983-11-04 1985-06-19 Takeda Chemical Industries, Ltd. Method for producing Microcapsule

Also Published As

Publication number Publication date
SE9102249L (sv) 1992-02-02
OA09387A (fr) 1992-09-15
MY107500A (en) 1995-12-30
US5213812A (en) 1993-05-25
IN178446B (cg-RX-API-DMAC7.html) 1997-05-03
DE4125542A1 (de) 1992-02-06
NL194637C (nl) 2002-10-04
CH682715A5 (fr) 1993-11-15
FR2665360B1 (fr) 1995-02-10
NO912986D0 (no) 1991-07-31
AU8146691A (en) 1992-02-06
IE65124B1 (en) 1995-10-04
ES2046083A1 (es) 1994-01-16
MA22245A1 (fr) 1992-04-01
AU649696B2 (en) 1994-06-02
FI104149B (fi) 1999-11-30
SE505734C2 (sv) 1997-10-06
GB9016885D0 (en) 1990-09-12
GR1001512B (el) 1994-02-28
BE1004772A3 (fr) 1993-01-26
NO300158B1 (no) 1997-04-21
CA2048270A1 (en) 1992-02-02
PT98497B (pt) 1997-10-31
ITMI911953A0 (it) 1991-07-15
PT98497A (pt) 1992-06-30
FI913646A0 (fi) 1991-07-31
NL194637B (nl) 2002-06-03
NO912986L (no) 1992-02-03
ZA915565B (en) 1992-04-29
NL9101306A (nl) 1992-03-02
AU5939394A (en) 1994-06-02
AU666808B2 (en) 1996-02-22
JP2818704B2 (ja) 1998-10-30
ITMI911953A1 (it) 1993-01-15
IT1251788B (it) 1995-05-26
JPH05178740A (ja) 1993-07-20
LU87982A1 (fr) 1992-04-15
DK175756B1 (da) 2005-02-14
DK141891A (da) 1992-02-02
SE9102249D0 (sv) 1991-07-26
CA2048270C (en) 1997-02-25
FI104149B1 (fi) 1999-11-30
KR920003962A (ko) 1992-03-27
NZ238981A (en) 1992-11-25
GR910100330A (en) 1992-08-31
HK33294A (en) 1994-04-22
ES2046083B1 (es) 1994-08-01
DK141891D0 (da) 1991-07-31
ATA152591A (de) 1993-01-15
TNSN91067A1 (fr) 1992-10-25
FI913646L (fi) 1992-02-02
IE912700A1 (en) 1992-02-12
FR2665360A1 (fr) 1992-02-07

Similar Documents

Publication Publication Date Title
AT396425B (de) Verfahren zur herstellung von zusammensetzungen, die stoffe anhaltend abgeben und so erhaltene zusammensetzungen
DE69632569T2 (de) Formulierungen und verfahren für eine verlängerte lokalanästhesie
DE69110150T2 (de) Mikrokapseln mit verzögerter Wirkstoffabgabe.
AT406225B (de) Formulierungen mit verlangsamter freisetzung wasserlöslicher peptide
DE69331387T2 (de) Biodegradierbare polymeren matrizen mit verzoegerter freisetzung von lokalanaesthetika
DE69329295T2 (de) Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung
DE69623981T2 (de) Nichtpolymere verabreichungssysteme mit verzögerter freisetzung
DE10045374B4 (de) Verfahren zur Herstellung von Mikroteilchen mit verzögerter Freisetzung
DE69814885T2 (de) Verfahren zur herstellung von arzneiformen mit kontrollierter wirkstoffabgabe auf polymerbasis
DE69107026T2 (de) Injizierbare galenische retardzubereitung.
DE68904326T2 (de) Physiologisch aktive substanzen enthaltende mikrosphaeren des polymilchsaeuretyps sowie verfahren zu deren herstellung.
DE69828252T2 (de) Zusammensetzung mit verzögerter freisetzung, wobei medikamente in mikropartikel aus hyaluronsäure eingekapselt sind
DE60127822T2 (de) Komprimierte mikropartikel für trockene injektion
DE69629797T2 (de) Matrix zur gesteuerten freisetzung von arzneistoffen
DE69332210T2 (de) Biologisch abbaubares, schmelzgesponnenes abgabesystem zur kontrollierten freisetzung
DE69327542T2 (de) Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
DE2842088A1 (de) Arzneimittel mit verzoegerter wirkstoffabgabe
DE3853853T2 (de) Verabreichungsformen für Pharmaka.
DE69009743T2 (de) Dosierungsform für dauerverabreichung.
DE69314028T2 (de) Mikrokügeln aus bioresorbierbarem polymer ohne tensid, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69328245T2 (de) Nifitepin enthaltende Arzneimittel und Verfahren
GB2246514A (en) Sustained release particles preparation
CH646052A5 (de) Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung.
DE69737515T2 (de) Micropartikel
EP1317254B1 (de) Retardpartikeldispersion

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee
ELJ Ceased due to non-payment of the annual fee